Depo-Provera 104 is a long-lasting injection that contains the active ingredient medroxyprogesterone acetate 104. It is a hormone that is used as a birth control while you're pregnant. This means that it can stop your sex drive or impair your thinking or concentration.
Depo-Provera 104 is an effective form of birth control. It works by stopping the production of gonadotropins, which are responsible for making you eggs and sperm. It's important to note that this form of birth control only works when you're sexually stimulated.
To find out how well Depo-Provera 104 works for you, talk with your doctor or pharmacist.
Yes! You can buy Depo-Provera 104 online through our website or call us at 1-800-222-1222.
For the effective version of Depo-Provera 104, the initial daily dose is one Depo-Provera 104 104gm single-dose vial (10 mg). This is great for those with busy schedules or limited periods.
For the effective version of Depo-Provera 104 of the name "C", the initial dose is two 10 mg single-dose vials (10 mg).
For the effective version of Depo-Provera 104 of the name "D", the initial dose is two 10 mg single-dose vials (10 mg).
For the effective version of Depo-Provera 104 of the name "F", the initial dose is 10 mg single-dose vials (10 mg).
For the effective version of Depo-Provera 104 of the name "G", the initial dose is 10 mg single-dose vials (10 mg).
Side effects can include headaches, muscle aches, indigestion, and breast tissue changes.
If you experience any of these side effects, stop taking Depo-Provera 104 and contact your doctor immediately.
If you experience an allergic reaction, stop taking Depo-Provera 104 and contact your doctor immediately.
If you experience a severe side effect, contact your doctor or nearest hospital.
The side effects of Depo-Provera 104 of the name "C" (concentration) are generally mild and temporary. However, if you have any side effects that are serious or have a serious underlying condition, you should stop taking Depo-Provera 104 of the name "C".
If you are pregnant, might become pregnant, or think you may be pregnant, talk to your doctor before using Depo-Provera 104 of the name "C". This may increase the risk of complications such as ectopic pregnancy, pre-eclampsia, and low birth weight.
If you are planning to become pregnant, think you may be pregnant, or are having sex, talk to your doctor before using Depo-Provera 104 of the name "C".
Depo-Provera 104 of the name "C" cannot be used by those who are pregnant, could become pregnant, or have any underlying medical conditions that affect the flow of blood in the placenta.
Do not use Depo-Provera 104 of the name "C" if you are taking or might become pregnant within the next 6 months.
The recommended dosage for Depo-Provera 104 of the name "C" is 10 mg once daily.
Depo-SubQ Provera 104 needs to be given by subcutaneous (hypodermic) injection once every 12 weeks. This is not an intramuscular injection and must be given by someone trained and knowledgeable on how to give a subcutaneous injection.
The main active ingredient in Depo-SubQ Provera 104 is Medroxyprogesterone acetate 104 mg.
The risks are low, but some women experience side effects when using Depo-SubQ Provera 104. Minor ones include (spotting) or some gain weight. Positive side effects are also a possibility, too — lighter bleeds are fairly common.
The chances of serious side effects from birth control pills are extremely unlikely, but some cases have been documented, such as unexplained vaginal bleeding, severe pelvic pain, severe abdominal pain, and bone pain. Depo-SubQ 104 has been associated with lower bone mineral density (BMD). However, pregnancy results in a greater potential loss of BMD. This method is not recommended for younger patients who have not yet reached their peak bone mass or patients with osteoporosis. Alternatives to Depo-SubQ Provera would be the pill, patch, ring.
If you experience swelling/itching of your face/throat/tongue, trouble breathing, or severe dizziness, this may indicate an allergic reaction, please call 911 or get to the emergency room to receive appropriate emergency medical treatment.
Do NOT take this medication if:
• you are allergic to medroxyprogesterone acetate or any of the other ingredients of this drug information.• you have a history of seizures/convulsions/convulsions/convulsions with medroxyprogesterone acetate or any other medications
• you have severe liver disease
• you have uncontrolled high blood pressure or congestive heart failure
Do not take this drug if this medication has been taken at higher dosage without any interactions with other medications or other drugs your doctor or healthcare provider has told you should you use it.
This medication should not be used by women who are pregnant, who are breastfeeding, or who have any predisposition such as liver disease, kidney disease, asthma, diabetes, or epilepsy.
A study published last year in the journalfound that women who took the contraceptive, Depo-Provera, were as much as five times more likely to develop mood swings and depression than those who did not.
But it also suggested that women who had been exposed to the drug had a greater risk of depression than those who had not. So did those who were also taking the drug, the study said.
Depo-Provera, the brand name for Depo-IUD, was not associated with any mood changes.
“While this is an open-label study, we acknowledge that it could have important implications for clinical practice,” Dr. Steven Nissen, a researcher at Yale University, said in a statement.
“We know the link between Depo-Provera use and depression. However, we also know that this study’s results do not apply to women who take Depo-IUDs or other contraceptive products.”
The research team is still working on whether these findings are real. If they are, it could lead to more harm, including depression.
Dr. Michael M. Haggerty, director of the department of psychiatry at Yale University, said his team is currently studying whether Depo-Provera use may be linked to increased risk of depression. He did not want to comment on the research.
“This is a complex study, and we’re still trying to understand why some women may have these negative symptoms,” he said.
Maintaining an open line of communication with patients is crucial.
“It’s very important that these data are used as a baseline for future studies that might include women who are taking Depo-IUDs. We are trying to establish whether these findings are real,” Dr. Haggerty said.
That said, M. R. Thompson, director of the U. S. Department of Health and Human Services, told The Associated Press, “This is an incredibly complex and controversial topic, and we’re just continuing to study it.”
Thompson said he was not sure why the researchers wanted to include women in their research.
“The researchers did a good job of explaining how Depo-Provera works in the body. The authors didn’t give the reasons behind their findings, but they certainly did point out that women who took Depo-Provera were as much as five times more likely to develop mood swings and depression,” Dr. Thompson said. “They also found that those who took Depo-IUDs or other contraceptive products also had greater risk of developing depression than those who did not.”
That could lead to more harm to those who are taking Depo-Provera, the study authors wrote.
Thompson acknowledged the study’s limitations, but he was not sure if it was true. The team is still working on whether the findings apply to women who have been exposed to Depo-IUDs or other contraceptive products.
“We’re not saying that the findings are statistically significant, but it’s very important that we get these data in time,” Dr. “If these findings are real, then it would be very difficult to prove anything in terms of the numbers.”
The authors noted that a large trial of Depo-Provera is currently ongoing, and that the trial is still underway. They also noted that they are not sure if the findings are real, or not.
A spokesperson for the Centers for Disease Control and Prevention, which regulates the use of Depo-Provera, said that it is not yet clear whether the findings could apply to women who have been exposed to the drug.
“The research is still ongoing and we’re just continuing to study it,” she said.
Jeffrey Nissen, director of the National Institute of Allergy and Infectious Diseases, said that his team is continuing to work on the findings. He said the study is still in its initial stages and hopes to have more results before publication.
Pharmacology:Pharmacodynamics:The proinflammatory activity of prohormone from progesterone-only family has been well documented in postmenopausal women (pre-menopausal women) and men (premature men) and it has been suggested that the administration of progesterone to pregnant women may be required to induce oestrogen secretion.1 This, in turn, may affect the maternal/fetal efficacy of or reduce the probability of menopause related oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic anovulation and spontaneous abortion.2,
Histopathology:Histopathological studies have demonstrated the presence of a group of folliculinary epithelium in the mucosa of the upper surface of the upper small intestine, accompanied by mild hyperplasia, atrophy and regression.3 The degree of hypersecretion was evaluated by the measurement of (3) B- and F-oestrogens, as well as the measurement of (4) Progesterone and Folic Acid, which are both crucial metabolites of prohormone which are vital for the proinflammatory activity.3 Our previous studies have shown, however, that there are no data on the potential effects of and on the upper surface of the upper small intestine accompanied by mild hypersecretion.1 In the present study, in order to assess the potential effects of prophylactically appropriate administration of progesteron on the upper surface of the upper small intestine accompanied by mild hypersecretion, the subjects were divided into 2 groups: group 1 received a daily dose of 5 mg of progesteron for 6 days and group 2 a dose of 10 mg of progesteron. In the placebo treated subjects, a further 6 days of progesteron treatment induced a marked improvement in the degree of hypersecretion and the measurement of (5) Progesterone and Folic Acid in the serum.1, In the subjects in the 10 mg/day and 5 mg/day treated groups, a further 4 weeks of progesteron treatment induced a significant improvement in the degree of hypersecretion and the measurement of (6) Progesterone.
Subjects were weighed and an oral progesterone-only oestradiol preparation was administered. The serum levels of Progesterone (ng/ml) and Folic Acid (μg/ml) were measured in order to assess the clinical relevance of the findings.1 Progesteron significantly increased the degree of hypersecretion and increased the measurement of (7) B- and F-oestrogens, as well as the measurement of (8) Progesterone. This effect was reversed in the 10 mg/day treated group. Therefore, subjects were advised to take progesteron 10 mg/day for 6 days at the lowest dose and then to take progesteron 10 mg/day every 8 hours for 6 days at the lowest dose. The dose of progesteron 10 mg/day was chosen as it has been shown to be effective in inducing oestrogen secretion from pregnant women.1 Therefore, the 10 mg/day dose of progesteron was chosen for this study and 10 mg/day for the 10 mg/day dose was chosen for the 10 mg/day dose in order to have a more complete assessment of the potential effects of prophylactically appropriate administration of progesteron on the upper surface of the upper small intestine accompanied by mild hypersecretion.1 Based on our previous studies, it can be assumed that a 10 mg/day dose of progesteron is sufficient to induce oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic oestrogenic and spontaneous abortion; therefore, subjects in the 10 mg/day treated group were advised to take progesteron 10 mg/day for 6 days at the lowest dose. The dose of progesteron 10 mg/day was chosen for this study and 10 mg/day for the 10 mg/day dose was chosen for the 10 mg/day dose in order to have a more complete assessment of the potential effects of prophylactically appropriate administration of progesteron on the upper surface of the upper small intestine accompanied by mild hypersecretion. The 10 mg/day dose was chosen for the 10 mg/day dose in order to have a more complete assessment of the potential effects of prophylactially appropriate administration of progesteron on the upper surface of the upper small intestine accompanied by mild hypersecretion.
Stade de France Pharmacy